Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14221228 | 0.80 | HDAC1 (0.70) | HDAC1KMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL25063717 | 0.79 | HDAC1 (0.65) | HDAC1KMT2ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL20999290 | 0.78 | HDAC1 (0.60) | HDAC1KMT2ASMN1; SMN2HTTRAB9A | |
| SCHEMBL19002729 | 0.77 | RAB9A (0.69) | HDAC1KMT2ASMN1; SMN2HTTRAB9A | |
| SCHEMBL23799315 | 0.75 | HDAC1 (0.76) | HDAC1KMT2ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL13874364 | 0.74 | MEN1 (0.51) | KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL24259735 | 0.73 | MEN1 (0.48) | KMT2AALDH1A1MEN1POLBHPGD | |
| SCHEMBL25772157 | 0.73 | HDAC1 (0.53) | HDAC1KMT2ASMN1; SMN2HTTRAB9A | |
| SCHEMBL25758742 | 0.72 | ALDH1A1 (0.62) | HDAC1KMT2ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL16213677 | 0.72 | ALDH1A1 (0.37) | KMT2ASMN1; SMN2HTTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250181-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250181-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | PDCD1, CD274, PDCD1LG2 | HDAC1 750/4885KMT2A 2529/4885SMN1; SMN2 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.